Connection

MENASHE BAR ELI to ErbB Receptors

This is a "connection" page, showing publications MENASHE BAR ELI has written about ErbB Receptors.
Connection Strength

0.981
  1. Receptor heterodimerization: a new mechanism for platelet-derived growth factor induced resistance to anti-epidermal growth factor receptor therapy for bladder cancer. J Urol. 2011 Feb; 185(2):693-700.
    View in: PubMed
    Score: 0.210
  2. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res. 2008 Mar 01; 14(5):1478-86.
    View in: PubMed
    Score: 0.173
  3. Targeting EGFR in bladder cancer. World J Urol. 2007 Dec; 25(6):573-9.
    View in: PubMed
    Score: 0.166
  4. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. Clin Cancer Res. 2006 Aug 01; 12(15):4671-7.
    View in: PubMed
    Score: 0.155
  5. A phase II study of gefitinib in patients with metastatic melanoma. Melanoma Res. 2011 Aug; 21(4):357-63.
    View in: PubMed
    Score: 0.055
  6. miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 2009 Aug 15; 15(16):5060-72.
    View in: PubMed
    Score: 0.048
  7. Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. Neoplasia. 2008 May; 10(5):489-500.
    View in: PubMed
    Score: 0.044
  8. Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer. J Urol. 2008 Jan; 179(1):353-8.
    View in: PubMed
    Score: 0.042
  9. Molecular correlates of gefitinib responsiveness in human bladder cancer cells. Mol Cancer Ther. 2007 Jan; 6(1):277-85.
    View in: PubMed
    Score: 0.040
  10. Uncoupling between epidermal growth factor receptor and downstream signals defines resistance to the antiproliferative effect of Gefitinib in bladder cancer cells. Cancer Res. 2005 Nov 15; 65(22):10524-35.
    View in: PubMed
    Score: 0.037
  11. Gefitinib reverses TRAIL resistance in human bladder cancer cell lines via inhibition of AKT-mediated X-linked inhibitor of apoptosis protein expression. Cancer Res. 2007 Feb 15; 67(4):1430-5.
    View in: PubMed
    Score: 0.010
  12. Antibodies to two defined regions of the transforming protein pp60src interact specifically with the epidermal growth factor receptor kinase system. Proc Natl Acad Sci U S A. 1984 Oct; 81(19):5911-5.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.